For research use only. Not for therapeutic Use.
Cilastatin-15N,d3 (CAS: 2738376-83-3), a premium pharmaceutical research compound designed for advanced antibiotic and renal studies. As an isotopically labeled analog of Cilastatin, it offers enhanced stability and precise isotopic tracking. Cilastatin-15N,d3 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel antibiotic therapies and renal protection strategies. Trusted by leading laboratories, Cilastatin-15N,d3 is your go-to solution for cutting-edge antibiotic and renal research. Unlock new possibilities in infection treatment and kidney protection with Cilastatin-15N,d3, where innovation meets reliability.
Catalog Number | S000243 |
CAS Number | 2738376-83-3 |
Molecular Formula | C16H23D3N15NO5S |
Purity | ≥95% |
Target | Bacterial |
IUPAC Name | (Z)-7-(2-(15N)azanyl-2-carboxy-1,1,2-trideuterioethyl)sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid |
InChI | InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11?/m1/s1/i9D2,11D,17+1 |
InChIKey | DHSUYTOATWAVLW-HUHQTNKFSA-N |
SMILES | [2H]C([2H])(C([2H])(C(=O)O)[15NH2])SCCCC/C=C(/C(=O)O)\NC(=O)[C@H]1CC1(C)C |
Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [2]. The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterialmetallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39(7):1629-31. [3]. Blanca Humanes, et al. Protective Effects of Cilastatin Against Vancomycin-Induced Nephrotoxicity. Biomed Res Int. 2015;2015:704382. [4]. P J Petersen, et al. In Vitro and in Vivo Activities of LJC10,627, a New Carbapenem With Stability to Dehydropeptidase I. Antimicrob Agents Chemother. 1991 Jan;35(1):203-7. |